Production (Stage)
Amicus Therapeutics, Inc.
FOLD
$6.22
-$0.04-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.25% | 32.29% | 32.58% | 29.98% | 25.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.25% | 32.29% | 32.58% | 29.98% | 25.74% |
| Cost of Revenue | 16.21% | 41.84% | 39.69% | 18.58% | 15.79% |
| Gross Profit | 29.65% | 31.30% | 31.83% | 31.40% | 27.01% |
| SG&A Expenses | 13.08% | 17.48% | 18.37% | 23.48% | 26.42% |
| Depreciation & Amortization | -6.16% | 8.56% | 24.08% | 44.32% | 69.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.93% | 4.52% | -0.75% | 0.36% | -5.39% |
| Operating Income | 182.70% | 146.35% | 113.03% | 80.26% | 66.38% |
| Income Before Tax | 97.71% | 80.84% | 63.74% | 48.29% | 34.30% |
| Income Tax Expenses | 295.93% | 1,744.23% | 343.65% | 353.72% | 169.05% |
| Earnings from Continuing Operations | 80.03% | 62.99% | 39.70% | 35.50% | 27.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.03% | 62.99% | 39.70% | 35.50% | 27.99% |
| EBIT | 182.70% | 146.35% | 113.03% | 80.26% | 66.38% |
| EBITDA | 214.29% | 164.94% | 122.30% | 86.41% | 70.60% |
| EPS Basic | 80.49% | 63.97% | 41.85% | 37.71% | 29.82% |
| Normalized Basic EPS | 100.04% | 85.55% | 76.14% | 60.14% | 45.94% |
| EPS Diluted | 80.49% | 63.97% | 41.85% | 37.71% | 29.82% |
| Normalized Diluted EPS | 100.04% | 85.55% | 76.14% | 60.14% | 45.94% |
| Average Basic Shares Outstanding | 2.53% | 3.13% | 3.63% | 3.45% | 2.58% |
| Average Diluted Shares Outstanding | 2.53% | 3.13% | 3.63% | 3.45% | 2.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |